uniQure (QURE) Gains from Sales and Divestitures (2017 - 2026)
uniQure (QURE) recorded quarterly Gains from Sales and Divestitures of $657285.0 in Q1 2026, down 15.39% quarter-over-quarter from $776882.0 in Q4 2025, and up 16.21% on a YoY basis from $565613.0 in Q1 2025.
uniQure (QURE) Gains from Sales and Divestitures (2017 - 2026) Analysis & Trends
uniQure's Gains from Sales and Divestitures history runs 10 years deep, the most recent figure standing at $657285.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures rose 16.21% year-over-year to $657285.0; the TTM figure through Mar 2026 stood at $657285.0 (up 16.21% YoY), while the FY2025 annual figure was $776882.0, up 1716.89% from the prior year.
- Gains from Sales and Divestitures was $657285.0 for Q1 2026 at uniQure, down from $776882.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $890994.0 in Q3 2024 to a low of $42759.0 in Q4 2024.
- Historically, Gains from Sales and Divestitures has averaged $415348.8 across 5 years, with a median of $283349.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures tumbled 94.21% in 2024, then soared 1716.89% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $213145.0 in 2022, then jumped by 246.45% to $738447.0 in 2023, then sank by 94.21% to $42759.0 in 2024, then jumped by 1716.89% to $776882.0 in 2025, then decreased by 15.39% to $657285.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $657285.0 (Q1 2026), $776882.0 (Q4 2025), and $66500.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 657,285.00 |
| Mar 31, 2026 | 657,285.00 |
| Dec 31, 2025 | 776,882.00 |
| Dec 31, 2025 | 776,882.00 |
| Sep 30, 2025 | 66,500.00 |
| Sep 30, 2025 | 66,500.00 |
| Jun 30, 2025 | 66,500.00 |
| Jun 30, 2025 | 66,500.00 |
| Mar 31, 2025 | 565,613.00 |
| Mar 31, 2025 | 565,613.00 |
| Dec 31, 2024 | 42,759.00 |
| Dec 31, 2024 | 42,759.00 |
| Sep 30, 2024 | 890,994.00 |
| Sep 30, 2024 | 890,994.00 |
| Jun 30, 2024 | 850,589.00 |
| Jun 30, 2024 | 850,589.00 |
| Mar 31, 2024 | 659,240.00 |
| Mar 31, 2024 | 659,240.00 |
| Dec 31, 2023 | 738,447.00 |
| Dec 31, 2023 | 738,447.00 |